4 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Allogeneic haematopoietic stem cell transplant, often after hypomethylating-agent cytoreduction; the only curative option.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · VIALE-A, azacitidine with venetoclax (28% with azacitidine and placebo) | - | 42% |
| Febrile neutropenia · VIALE-A, azacitidine with venetoclax (19% with azacitidine and placebo) | - | 42% |
| Nausea · VIALE-A, azacitidine with venetoclax (35% with azacitidine and placebo) | 44% | - |
| Injection-site reactions · Subcutaneous azacitidine alone in myelodysplastic syndromes (US label Study 4, N=175); injection-site erythema 43% | 29% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Azacitidine or decitabine (or oral decitabine-cedazuridine) until progression; supportive care with transfusion and growth factors.
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Oral decitabine-cedazuridine is a pill version of the hypomethylating chemotherapy that, since May 2026, lets older AML patients take their whole venetoclax regimen at home.
Red cell and platelet transfusions, iron and erythropoiesis-stimulating agents keep patients safe through chemotherapy and marrow failure; restrictive thresholds and ESA caution reflect trials showing more is not better.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · VIALE-A, azacitidine with venetoclax (28% with azacitidine and placebo) | - | 42% |
| Febrile neutropenia · VIALE-A, azacitidine with venetoclax (19% with azacitidine and placebo) | - | 42% |
| Nausea · VIALE-A, azacitidine with venetoclax (35% with azacitidine and placebo) | 44% | - |
| Injection-site reactions · Subcutaneous azacitidine alone in myelodysplastic syndromes (US label Study 4, N=175); injection-site erythema 43% | 29% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Hydroxyurea (superior to etoposide in the randomised GFM trial, and not bettered by decitabine on event-free survival in the DACOTA trial); ruxolitinib in trials for symptomatic proliferative disease.
Hydroxyurea is a cheap, decades-old pill that lowers high blood counts in polycythaemia vera and essential thrombocythaemia and is also the main drug for sickle cell disease.
Ruxolitinib was the first JAK inhibitor: it shrinks the spleen and relieves symptoms in myelofibrosis and controls blood counts in polycythaemia vera, without eliminating the disease clone.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Allogeneic transplant; azacitidine as bridging therapy (FDA approval in May 2022 for newly diagnosed JMML in children aged one month and older; the EU licence for azacitidine has no JMML indication); watchful waiting for some CBL- or Noonan-associated cases that regress spontaneously.
A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · VIALE-A, azacitidine with venetoclax (28% with azacitidine and placebo) | - | 42% |
| Febrile neutropenia · VIALE-A, azacitidine with venetoclax (19% with azacitidine and placebo) | - | 42% |
| Nausea · VIALE-A, azacitidine with venetoclax (35% with azacitidine and placebo) | 44% | - |
| Injection-site reactions · Subcutaneous azacitidine alone in myelodysplastic syndromes (US label Study 4, N=175); injection-site erythema 43% | 29% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.